Hou J, Weng R, Gu X, Zhao J, Li X, Liu S. Int J Gen Med. 2025;18:44254436. doi:10.2147/IJGM.S538127 After publication, the authors have identified data errors in the Abstract-Results section on page 4425 and in the The Diagnostic Value of Exosomal mascRNA for ACS in the Results section on page 4430. Abstract-Results on page 4425: Second sentence should read from Exosomal mascRNA demonstrated a diagnostic value for ACS (AUC: 0.763, 95% CI: 0.7020.824). Combined detection of exosomal mascRNA with cTnI improved the diagnostic preformation for ACS (AUC: 0.866, 95% CI: 0.8150.916). to Exosomal mascRNA demonstrated a diagnostic value for ACS (AUC: 0.776, 95% CI: 0.7210.830). Combined detection of exosomal mascRNA with cTnI improved the diagnostic preformation for ACS (AUC: 0.884, 95% CI: 0.8430.923). The Diagnostic Value of Exosomal mascRNA for ACS in the Results section on page 4430 Second and third sentences should read from Our data revealed that exosomal mascRNA serves as a diagnostic predictor for ACS, with an AUC of 0.763 (95% CI: 0.7020.824) and cutoff value of 1.173 (Figure 5). The predictive performance of mascRNA improved when combined with cTnI, with the AUCs increased to 0.866 (95% CI: 0.8150.916) (Figure 5). to Our data revealed that exosomal mascRNA serves as a diagnostic predictor for ACS, with an AUC of 0.776 (95% CI: 0.7210.830) and cutoff value of 1.480 (Figure 5). The predictive performance of mascRNA improved when combined with cTnI, with the AUCs increased to 0.884 (95% CI: 0.8430.923) (Figure 5). The authors advised that the above corrected data align with the published Figure 5. Notably, the accurate data were presented in the Discussion section (Page 4433, paragraph 2). The authors apologize for these oversights.
Hou et al. (Wed,) studied this question.